Claims analysis of 88,463 #RA pts (2006-2015) finds no greater risk of cardiovascular events w/ Tocilizumab (11.8/1000 PY) compared to TNF inhibitors (15/1000PY) or abatacept; suggesting no net increase in CVD w/ occ hyperlipidemia seen w/ TCZ https://t.co/6L8aKlLGta